The quadrivalent Gardasil® vaccine against human papilloma virus (HPV) was granted a Marketing Authorisation (MA) variation on 27 March 2014 allowing the administration of the vaccine in two doses with a 6-month spacing to young girls aged 9 to 13 years.
Upon analysis of these new data, the French High Council of public health (HCSP) reminds that, in accordance with its notice of 28 September 2012 and the current immunisation schedule, vaccination against papilloma virus infections is recommended in young girls aged 11 to 14 years, with a limited catch-up at the age of 19.
It recommends that:
young girls aged 11 to 13 when receiving the first dose, and for whom the Gardasil® vaccine was chosen for their HPV immunisation, be vaccinated according to a 2-dose schedule with a 6-month spacing;
for young girls aged 14 to 19 years, the 3-dose schedule be maintained;
for young girls aged 11 to 13 when given the first dose, if the second vaccine dose is administered within six months of the first dose, a third dose must always be administered.
- Recommendation
- Europe
- France
- Human papillomavirus (HPV)
